ESTETROL ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H24O4
Molecular Weight	304.3808
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12[C@@H](O)[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]3([H])C4=C(CC[C@@]23[H])C=C(O)C=C4

InChI

InChIKey=AJIPIJNNOJSSQC-NYLIRDPKSA-N

InChI=1S/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3/t12-,13-,14-,15-,16-,17+,18+/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18464023 | https://www.ncbi.nlm.nih.gov/pubmed/26394847 | https://www.ncbi.nlm.nih.gov/pubmed/24997853 | http://adisinsight.springer.com/drugs/800044874

Estetrol is the natural human fetal selective estrogen receptor modulator. It is synthesized exclusively by the human fetal liver during pregnancy. Estetrol has a moderate affinity for human estrogen A receptor (ERa) and estrogen B receptor (ERb). Estetrol may be suitable as a potential drug for human use in applications such as hormone replacement therapy (vaginal atrophy, hot flushes), contraception and osteoporosis. The most common drug-related adverse events were lower abdominal pain, nausea, headache, dysmenorrhoea, breast enlargement and acne. Estetrol had been in clinical trials for the treatment of breast and prostate cancers.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Estrogen receptor alpha 127 Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18464023	Modulator 828		4.9 nM [Ki]
Estrogen receptor beta 110 Target ID: CHEMBL242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18464023	Modulator 828		19.0 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Pregnancy 65 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27153745 https://www.ncbi.nlm.nih.gov/pubmed/26394847	Preventing	Phase III 656	Unknown Approved Use Unknown
Breast cancer 434 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24997853	Primary	Phase II 1132	Unknown Approved Use Unknown
Prostate cancer 178 Sources: https://clinicaltrials.gov/ct2/show/NCT02718378	Primary	Phase I 428	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/18464021 Page: p.34	healthy, ADULT n = 6 Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/18464021 Page: p.34	Sources: https://pubmed.ncbi.nlm.nih.gov/18464021 Page: p.34
15 mg 1 times / day multiple, oral Minumum effective dose Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32379217 Page: p.855	unhealthy, ADULT n = 49 Health Status: unhealthy Condition: reproductive system disease Age Group: ADULT Sex: F Food Status: UNKNOWN Population Size: 49 Sources: https://pubmed.ncbi.nlm.nih.gov/32379217 Page: p.855	Disc. AE: uterine bleedin... AEs leading to discontinuation/dose reduction: uterine bleedin (grade 3, 2%) Sources: https://pubmed.ncbi.nlm.nih.gov/32379217 Page: p.855
60 mg 1 times / day multiple, oral Studied dose Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33242131 Page: p.1837	unhealthy, ADULT n = 3 Health Status: unhealthy Condition: breast cancer Age Group: ADULT Sex: F Food Status: UNKNOWN Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/33242131 Page: p.1837	Sources: https://pubmed.ncbi.nlm.nih.gov/33242131 Page: p.1837

AEs

AE	Significance	Dose	Population
uterine bleedin	grade 3, 2% Disc. AE	15 mg 1 times / day multiple, oral Minumum effective dose Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32379217 Page: p.855	unhealthy, ADULT n = 49 Health Status: unhealthy Condition: reproductive system disease Age Group: ADULT Sex: F Food Status: UNKNOWN Population Size: 49 Sources: https://pubmed.ncbi.nlm.nih.gov/32379217 Page: p.855

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P007XA8	https://www.1pchem.com/search?query=1P007XA8
Angene	AGN-PC-0WH1SZ	http://www.angenechemical.com/productshow/AGN-PC-0WH1SZ.html
Axon MedChem	1926	https://www.axonmedchem.com/product/1926
BOC Sciences	15183-37-6	http://www.bocsci.com/description.asp?cas=15183-37-6
Cayman Chemical	18232	http://www.caymanchem.com/app/template/Product.vm/catalog/18232
Chem Scene	CS-0008552	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0008552
MolPort	MolPort-042-665-780	https://www.molport.com/shop/molecule-link/MolPort-042-665-780
MolPort	MolPort-046-856-563	https://www.molport.com/shop/molecule-link/MolPort-046-856-563
Ryan Scientific	101-93964	https://ryansci.com/products?q=101-93964&list_q=&search_type=exact
Tetrahedron	TS75748	http://www.thsci.com/search.do?q=TS75748
Toronto Research Chemicals	E668450	https://www.trc-canada.com/product-detail/?CatNum=E668450
eMolecules	31225888	https://orderbb.emolecules.com/search/#?query=31225888

PubMed

Title	Date	PubMed
		252160577
[Estrogen: estrone (E1), estradiol (E2), estriol (E3) and estetrol (E4)].	2005 Aug	16149545
Determination of steroids in human plasma using temperature-dependent inclusion chromatography for metabolomic investigations.	2006 Feb 3	16364333
Characterization of human fetal cord blood steroid profiles in relation to fetal sex and mode of delivery using temperature-dependent inclusion chromatography and principal component analysis (PCA).	2007 Aug 15	17625993
In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism.	2008	18464025
First human exposure to exogenous single-dose oral estetrol in early postmenopausal women.	2008	18464021
Preventive effect of oral estetrol in a menopausal hot flush model.	2008	18464017
Interaction of native alpha-cyclodextrin, beta-cyclodextrin and gamma-cyclodextrin and their hydroxypropyl derivatives with selected organic low molecular mass compounds at elevated and subambient temperature under RP-HPLC conditions.	2008 Aug	18563397
Determination of endocrine disrupting compounds using temperature-dependent inclusion chromatography: I. Optimization of separation protocol.	2009 Oct 30	19362314
[Estrogen: estrone (E1), estradiol (E2), estriol (E3) and estetrol (E4)].	2010 Jul	20960812

Patents

Sample Use Guides

In Vivo Use Guide

15 mg administered once daily for 13 consecutive cycles following a 24/4-day regimen.

Route of Administration: Oral

In Vitro Use Guide

Binding of Estetrol at the glucocorticoid, progesterone and testosterone receptors was only 11–15% at a concentration of 10 uM/l. Estetrol at a high concentration of 10 uM/l did not inhibit the major cytochrome P450 enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4.

Name

Type

Language

ESTETROL ANHYDROUS

Common Name

English

ESTETROL

Preferred Name

English

E4

Code

English

Estetrol [WHO-DD]

Common Name

English

ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL, (15.ALPHA.,16.ALPHA.,17.BETA.)-

Systematic Name

English

ESTETROL (ANHYDROUS) [USAN]

Common Name

English

ESTRA-1,3,5(10)-TRIENE-3,15.ALPHA.,16.ALPHA.,17.BETA.-TETROL

Systematic Name

English

estetrol [INN]

Common Name

English

ESTETROL (E4)

Common Name

English

E-4

Code

English

15.ALPHA.-HYDROXYESTRIOL

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

678119